文献速递中毒与环境急症重症综合管理与镇静镇痛

乙酰半胱氨酸的安全性:医源性过量病例及其相关并发症的范围综述

Safety of acetylcysteine: a scoping review of iatrogenic overdose cases and their associated complications.
PubMed 文献 · Clin Toxicol (Phila) · 2026-06-29
一句话结论医源性乙酰半胱氨酸过量与高致残致死率相关,暴露≥1000 mg/kg与脑水肿显著相关(P=0.0476),作者建议简化给药方案并加强电子病历与监测等安全措施。

该范围综述通过Covidence检索MEDLINE等数据库,纳入16篇报告医源性乙酰半胱氨酸过量导致临床恶化的文献,其中14例为乙酰半胱氨酸本身毒性,2例为稀释液过量致低钠血症。14例中毒性过量患者中85.7%为女性(平均年龄18岁),错误来源于电子病历、药房、医生和护理多个环节。可分析结局的10例中,乙酰半胱氨酸暴露≥1000 mg/kg与脑水肿显著相关(P=0.0476);5例癫痫发作中4例(80%)接受≥1000 mg/kg,但该暴露与癫痫发作无显著相关(P=0.52)。死亡6例中4例使用三袋方案、2例使用两袋方案,功能结局呈双峰分布。

要点

  • 14例乙酰半胱氨酸过量病例中85.7%为女性,平均年龄18岁,错误涉及电子病历、药房、医生及护理多环节。
  • 可分析结局的10例中,乙酰半胱氨酸暴露≥1000 mg/kg与脑水肿显著相关(P=0.0476)。
  • 5例癫痫发作患者中4例(80%)接受≥1000 mg/kg乙酰半胱氨酸,但该暴露与癫痫发作未达统计学显著(P=0.52)。
  • 死亡与严重残疾、溶血性尿毒症综合征及功能结局在不同剂量阈值间无显著差异。
  • 6例死亡中4例使用三袋方案、2例使用两袋方案;功能结局呈双峰分布,多数完全恢复或死亡,少数遗留持续缺陷。

适用人群与场景

  • 因乙酰半胱氨酸给药或输注错误导致临床恶化的医源性过量病例;排除已知副作用(如无过量的过敏样反应)或仅有实验室异常而无临床毒性的病例。

诊断标准与关键阈值

  • 乙酰半胱氨酸暴露≥1000 mg/kg为脑水肿的相关阈值(P=0.0476)。

红旗征与不能漏的情况

  • 脑水肿可在临床恶化前有较长滞后 period,需早期识别和干预。
  • 癫痫发作:5例患者中4例(80%)接受≥1000 mg/kg乙酰半胱氨酸。
  • 溶血性尿毒症综合征可在存活较久的患者中观察到。
  • 死亡:6例死亡中4例使用三袋方案、2例使用两袋方案。

研究设计与关键结果

  • 范围综述纳入16篇报告,其中14例描述乙酰半胱氨酸过量本身毒性(分析集),2例描述稀释液过量致低钠血症。
  • 14例中毒性过量患者中85.7%为女性,平均年龄18岁;错误来源于电子病历、药房、医生和护理。
  • 14例中10例有足够信息按乙酰半胱氨酸暴露分层分析结局。
  • 乙酰半胱氨酸暴露≥1000 mg/kg与脑水肿显著相关(P=0.0476)。
  • 5例癫痫发作患者中4例(80%)接受≥1000 mg/kg乙酰半胱氨酸,但该暴露与癫痫发作无显著相关(P=0.52)。
  • 死亡与严重残疾、溶血性尿毒症综合征及功能结局在不同剂量阈值间无显著差异。
  • 功能结局呈双峰分布:多数患者完全恢复或死亡,少数遗留持续缺陷。
  • 6例死亡中4例使用三袋方案、2例使用两袋方案。

证据类型、等级与局限

  • 证据类型:范围综述(scoping review),纳入16篇病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,鉴于乙酰半胱氨酸暴露≥1000 mg/kg与脑水肿的显著关联及临床恶化前的较长滞后期,早期识别和干预很重要。
  • 作者认为,多环节系统失败而非单一孤立错误占主导,提示需要超越方案修订的安全防护措施。
  • 作者认为,证据支持考虑对乙酰半胱氨酸给药方案进行以安全为重点的变更,包括采用简化给药方案、改进电子病历、安全防护和早期针对性干预。
  • 作者认为,标准化监测方案可能进一步减少传统及扩展用途中的可预防伤害。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acetylcysteine is the standard antidote for acetaminophen (paracetamol) toxicity and is widely considered safe when administered appropriately. However, an increasing number of case reports have documented serious adverse outcomes following its improper administration, including cerebral edema, hemolytic uremic syndrome, and death. As acetylcysteine is increasingly utilized for roles beyond acetaminophen overdose, its broader application introduces more opportunity for error. This review aims to systematically evaluate published cases of iatrogenic acetylcysteine overdose to characterize the risks, patterns of error, and outcomes associated with these events.

METHODS: We conducted a scoping review of peer-reviewed literature describing iatrogenic acetylcysteine overdose. Articles were identified using Covidence through a comprehensive search of MEDLINE and additional databases. Search terms and strategy were guided by medical subject heading analysis. Included cases reported dosing or infusion-related errors that led to clinical deterioration. Cases involving known side effects (e.g., anaphylactoid reactions without overdose) or abnormal lab values without clinical toxicity were excluded. Extracted variables included dosing protocol, route, type of error, timing of events, complications, and neurological outcomes utilizing the modified Rankin scale, when available.

RESULTS: A total of 16 reports met the inclusion criteria, with 14 describing toxicity from acetylcysteine overdose itself (analytic set) and two describing hyponatremia resulting from excess diluent volume. Among the 14 toxic overdose patients, 85.7% were female (mean age 18 years). Errors stemmed from the electronic medical record, pharmacy, provider, and nursing errors. Of the 14 reported acetylcysteine overdoses, 10 included sufficient information to analyze outcomes stratified by acetylcysteine exposure. Acetylcysteine exposure ≥1000 mg/kg was significantly associated with cerebral edema (P = 0.0476). Among the five patients who developed seizures, four (80%) had received ≥1000 mg/kg of acetylcysteine. However, this exposure was not significantly associated with seizure occurrence (P = 0.52). Death and severe disability, hemolytic uremic syndrome, and functional outcomes were not significantly different by dose threshold. Functional outcomes revealed a bimodal distribution: most patients either recovered fully or died, with a minority experiencing persistent deficits. Among the six fatal cases, four occurred in patients receiving three-bag regimens, and two occurred in those receiving two-bag protocols.

DISCUSSION: The significant association between acetylcysteine exposure ≥1000 mg/kg and cerebral edema underscores the importance of early recognition and intervention, particularly given the substantial lag period before clinical decline. Additionally, the predominance of multi-level system failures rather than one isolated error highlights the need for safeguards beyond protocol revision alone. As acetylcysteine expands to indications beyond toxicologic emergencies, these findings reinforce the importance of implementing additional safety measures across clinical settings.

CONCLUSION: Iatrogenic acetylcysteine overdose is associated with high morbidity and mortality, with cerebral edema at very large doses contributing to rapid clinical deterioration, and frequently, death. In patients who survive longer, complications such as hemolytic uremia syndrome were observed. Evidence from this review supports the consideration of safety-focused changes in acetylcysteine administration protocols, including the adoption of simplified dosing regimens, improved electronic medical records, safeguards, and early targeted interventions. Standardizing monitoring protocols may further mitigate preventable harm in both traditional and expanded use cases.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Baker MB, Young J, Binda DD, et al. Safety of acetylcysteine: a scoping review of iatrogenic overdose cases and their associated complications. Clin Toxicol (Phila). 2026. PMID: 42370551. doi:10.1080/15563650.2026.2673132

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。